Loading
A phase 3 trial of Savolitinib in non-small-cell lung cancer and small-cell lung cancer, run by Hutchmed, active and no longer recruiting.
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT05009836 by Hutchmed, with 412 participants planned, started 2021-09-06 and due to reach its primary completion in 2028-05-30. Interventions recorded: Savolitinib, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Savolitinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Savolitinib, Hutchmed.
Shares Savolitinib, Hutchmed, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Savolitinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.